Dr. Vogelzang Discusses PROSPECT Trial for Prostate Cancer

Dr. Nicholas Vogelzang Discusses Radium-223 in Prostate CancerПодробнее

Dr. Vogelzang Discusses the Addition of Chemotherapy to ADT in Men With Prostate CancerПодробнее

Rationale for Phase III PROSPECT Trial in Prostate CancerПодробнее

Dr. Vogelzang Discusses the Cabozantinib Trial DesignПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancerПодробнее

Dr. Vogelzang Discusses the Prostate Health CocktailПодробнее

Dr. Vogelzang Discusses Treatment With Radium-223 and Chemotherapy for Prostate CancerПодробнее

Dr. Nicholas Vogelzang Discusses Latest Advances in Prostate CancerПодробнее

Dr. Nicholas Vogelzang Discusses PSMA ADC in Prostate CancerПодробнее

Dr. Vogelzang Discusses Mortalities in Cabozantinib TrialПодробнее

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugsПодробнее

Dr. Vogelzang Describes Two Additional Analyses of the ALSYMPCA TrialПодробнее

Dr. Oliver Sartor Discusses Radium-223 in Early Prostate CancerПодробнее

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancerПодробнее

Dr. Nicholas Vogelzang Discusses Sequencing Abiraterone and EnzalutamideПодробнее

Dr. George on Results of Abi Race Trial in Prostate CancerПодробнее

2013 OncPrac Summit: Nicholas Vogelzang on how he treats metastic prostate cancerПодробнее

New diagnostics for prostate cancerПодробнее

Nicholas J. Vogelzang, MD, discusses the difference in mortality in the PROSPER and SPARTAN trialsПодробнее